Abstract
Between 14 December 1989 and 17 December 1993, 43 patients undergoing kidney transplantation alone at the Children's Hospital of Pittsburgh received FK506 as the primary immunosuppressive agent. The mean recipient age was 10.2±4.8 years (range 0.7–17.4 years), with 7 (16%) children under 5 years of age and 2 (5%) under 2 years of age. Fifteen (35%) children underwent retransplantation, and 5 (12%) had a panel-reactive antibody level greater than 40%. Twenty-two (51%) transplants were with cadaveric donors and 21 (49%) were with living donors. The mean follow-up was 25±14 months; there were no deaths; 1- and 3-year actuarial graft survival was 98% and 85%. The mean serum creatinine and blood urea nitrogen were 1.2±0.6 mg/dl and 26±11 mg/dl; the calculated creatinine clearance was 75±23 ml/min per 1.73 m2. Twenty-four (62%) patients have been successfully with-drawn from steroids and 24 (62%) require no anti-hypertensive medication. Improved growth was seen, particularly in pre-adolescent children off steroids. Between 28 July 1990 and 2 December 1993, 24 children were referred for rescue therapy with FK506, 14.6±16.4 months (range 1.1–53.2 months) after transplantation. Nineteen (79%) were referred because of resistant rejection; 4 (17%) were referred because of proteinuria; 1 (4%) was switched because of steroid-related obesity. There were no deaths; 1-and 2-year graft survival was 75% and 68%; 17 (71%) patients were successfully rescued, including 1 of 2 patients who arrived on dialysis; 4 (24%) of the successfully rescued patients were weaned off steroids. While not without side effects, which include nephrotoxicity, neurotoxicity, diabetogenicity, and viral complications, FK506 appears to be an effective immunosuppressive agent for both primary and rescue therapy after kidney transplantation. Its steroid-sparing qualities may be of particular importance in the pediatric population.
Similar content being viewed by others
References
First International Workshop on “FK506 (1987) A potential breakthrough in immunosuppression”. Transplant Proc 19 [Suppl 6]: 3–103
Armitage JM, Kornos RL, Fung JJ, Starzl TE (1991) The clinical trial of FK506 as a primary and rescue immunosuppression in adult cadaveric transplantation. Transplant Proc 23:3054–3057
Griffith BO, Bando K, Hardesty RL, Armitage JM, Keenan RJ, Paradis IL, Fung JJ, Starzl TE (1994) Prospective randomized trial of FK506 vs. cyclosporine after human pulmonary transplantation. Transplantation 57:848–851
Fung JJ, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Takaya S, Allessiani M, Demetris A, Bronsther O, Martin M, Mieles L, Selby R, Doyle H, Stieber A, Casavilla A, Starzl TE (1991) A randomized trial of primary liver transplantation under immunosuppression with FK506 vs. cyclosporine. Transplant Proc 23:2977–2983
Starzl TE, Fung JJ, Jordan M, Shapiro R, Tzakis A, McCauley J, Johnston J, Iwaki Y, Jain A, Alessiani M, Todo S (1990) Kidney transplantation under FK506. JAMA 264:63–67
Todo S, Fung JJ, Starzl TE, Tzakis A, Demetris AJ, Kormos R, Jain A, Allessiani M, Takaya S, Shapiro R (1990) Liver, kidney and thoracic organ transplantation under FK506. Ann Surg 212:295–305
Shapiro R, Jordan M, Fung JJ, McCauley J, Johnston J, Iwaki Y, Tzakis A, Hakala T, Todo S, Starzl TE (1991) Kidney transplantation under FK506 immunosuppression. Transplant Proc 23:920–923
Shapiro R, Jordan M, Scantlebury V, Fung JJ, Jensen C, Vivas C, McCauley J, Irish WD, Mitchell S, Demetris AJ, Randhawa P, Jain A, Tzakis A, Hakala TR, Simmons RL, Starzl TE (1993) Randomized trial of FK506/prednisone vs. FK506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc 25:669–672
Shapiro R, Jordan M, Scantlebury V, Vivas C, Fung JJ, McCauley J, Tzakis A, Randhawa P, Demetris AJ, Irish W, Mitchell S, Jensen C, Jain A, Hakala T, Simmons R, Starzl TE (1995) A prospective, randomized trial of FK506 in renal transplantation—a comparison between double and triple drug therapy. Clin Transplant (in press)
Todo S, Tzakis A, Reyes J, Abu-Elmagd K, Casavilla A, Nour BM, Selby R, Fung JJ, Van Thiel D, Starzl TE (1991) Clinical small bowel or small bowel plus liver transplantation under FK506. Transplant Proc 23:3093–3098
Ricordi C, Tzakis A, Carroll P, Zeng Y, Rilo HLR, Alejandro R, Shapiro R, Fung JJ, Mintz DH, Starzl TE (1991) Human islet allotransplantation under FK506. Transplant Proc 23:3207
Jensen C, Jordan M, Schneck F, Shapiro R, Tzakis A, Hakala T, Starzl TE (1991) Pediatric renal transplantation under FK506 immunosuppression. Transplant Proc 23:3075–3077
Schneck F, Jordan M, Jensen C, Shapiro R, Tzakis A, Scantlebury V, Ellis D, Gilboa N, Simmons R, Hakala T, Starzl TE (1992) Pediatric renal transplantation under FK506 immunosuppression. J Urol 147:1585–1587
Ellis D, Shapiro R, Jordan ML, Scantlebury VP, Gilboa N, Hopp L, Weichler N, Simmons RL (1995) Comparison of FK506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol (in press)
Scantlebury V, Shapiro R, Tzakis A, Jordan M, Vivas C, Ellis D, Gilboa N, Hopp L, Irish W, Mitchell S, Hakala TR, Simmons RL, Starzl TE (1994) Pediatric kidney transplantation at the University of Pittsburgh. Transplant Proc 26:46–47
Shapiro R, Tzakis A, Scantlebury V, Jordan M, Vivas C, Ellis D, Gilboa N, Irish W, Hopp L, Reyes J, Hakala T, Simmons RL, Starzl TE (1995) Improving results of pediatric kidney transplantation. J Am Coll Surg (in press)
Jordan ML, Shapiro R, Jensen C, Scantlebury V, Fung J, Tzakis A, McCauley J, Jain A, Demetris, A., Randhawa P, Simmons RL, Hakala TR, Starzl TE (1991) FK506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc 23:3078–3081
Jordan M, Shapiro R, Vivas C, Scantlebury V, Randhawa P, Carrieri G, McCauley J, Demetris AJ, Tzakis A, Fung JJ, Simmons RL, Hakala TR, Starzl TE (1995) FK506 rescue for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (in press)
McCauley J, Shapiro R, Jordan M, Scantlebury V, Vivas C, Jensen C, Starzl TE (1993) FK506 in the management of nephrotic syndrome after renal transplantation. Transplant Proc 25:1351–1354
Schwartz GJ, Gauthier B (1985) A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 106:522–526
McCauley J, Takaya S, Fung J, Tzakis A, Abu-Elmagd K, Jain A, Todo S, Starzl TE (1991) The question of FK506 nephrotoxicity after liver transplantation. Transplant Proc 23:1444–1447
Starzl TE, Abu-Elmagd K, Tzakis A, Fung JJ, Porter KA, Todo S (1991) Selected topics on FK506, with special references to rescue of extrahepatic whole organ grafts, transplantation of “forbidden organs”, side effects, mechanisms, and practical pharmacokinetics. Transplant Proc 23:914–919
Starzl TE (1993) FK506 versus cyclosporine. Transplant Proc 25:511–512
Demetris AJ, Banner B, Fung J, Shapiro R, Jordan M, Starzl TE (1991) Histopathology of human renal allograft rejection under FK506: a comparison with cyclosporine. Transplant Proc 23:944–946
Randhawa PS, Shapiro R, Jordan M, Starzl TE, Demetris AJ (1993) The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506: clinical significance and comparison with cyclosporine. Am J Surg Pathol 17:60–68
Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffmann RS (1992) RS-61443—a phase I clinical trial and pilot rescue study. Transplantation 53:428–432
Makowka L, Chapman F, Cramer DV (1993) Historical development of Brequinar sodium as a new immunosuppressive drug for transplantation. Transplant Proc 25:2–7
Morris RE (1991) Rapamycin: FK506's fraternal twin or distant cousin? Immunol Today 12:137–140
Chong AS-F, Gebel H, Finnegan A, Petraitis EE, Jiang XL, Sankary HN, Foster P, Williams JW (1993) Leflunomide, a novel immunomodulatory agent: in vitro analyses of the mechanism of immunosuppression. Transplant Proc 25:747–749
Morris RE (1991) ± 15-Deoxyspergualin: a mystery wrapped within an enigma. Clin Transplant 5:530–533
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shapiro, R., Scantlebury, V.P., Jordan, M.L. et al. FK506 in pediatric kidney transplantation—Primary and rescue experience. Pediatr Nephrol 9 (Suppl 1), S43–S48 (1995). https://doi.org/10.1007/BF00867683
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00867683